Materias dentro de su búsqueda.
Mostrando 421 - 440 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.34s Limitar resultados
  1. 421
    “…To develop a more effective therapy for human epidermal growth factor receptor 2 (HER2)-positive cancer, we explored a novel ADCs composed of anti-HER2 scFv–HSA fusion antibodies conjugates with a potent cytotoxic drug DM1. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
  2. 422
    “…The human epidermal growth factor receptor (HER1) and its partner HER2 are extensively described oncogenes and validated targets for cancer therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies
  3. 423
    “…In total, 1138, 301 and 344 patients had IHC-determined HER2-negative, HER2-borderline and HER2-positive disease, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry
  4. 424
    “…The aims of this study were to assess the prognostic value of the HER2 exon 27 mutations in breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
  5. 425
    por Komolova, Masha, Lipnitsky, Jane Y.
    Publicado 2018
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “I Want Her to Make Correct Decisions on Her Own:” Former Soviet Union Mothers' Beliefs about Autonomy Development
  6. 426
    “…BACKGROUND: The HER3 receptor functions as a major cause of drug resistance in cancer treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
  7. 427
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
  8. 428
    “…PURPOSE: Anti-human epidermal growth factor receptor 2 (HER2) therapies are associated with interstitial lung disease (ILD), also referred to as pneumonitis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
  9. 429
    “…BACKGROUND: Breast cancer brain metastases (BCBM) commonly develop in human epidermal growth factor 2-positive (HER2+) breast cancer, but BCBM patients are underrepresented in clinical trials, leading to a lack of knowledge on the efficacy of HER2-targeted therapy in this population. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
  10. 430
    “…BACKGROUND: The prevalence of HER2 alterations in pan-cancer indicates a broader range of application of HER2-targeted therapies; however, biomarkers for such therapies are still insufficient and limited to breast cancer and gastric cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
  11. 431
    “…Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
  12. 432
    “…BACKGROUND: Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
  13. 433
    “…The KATHERINE trial changes the outlook for high-risk HER2-positive breast cancer, which suggests that escalation treatment for patients with residual disease after neoadjuvant anti-HER2 therapy may improve survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
  14. 434
    “…Our aim was to develop a more efficient purification method for the cytotoxic conjugate Z(HER2:2891)DCS-MMAE that targets human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
  15. 435
    “…BACKGROUND: Compared to the other members of human epidermal growth factor family receptors (HER), the role of HER3 has not been well defined in laryngeal cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma
  16. 436
    “…Complete blockade of the HER2 protein itself and HER signaling network is critical to achieving effective HER2-targeted therapies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2
  17. 437
    “…A methodology was developed for absolute quantification of receptor surface density ρ(R), and molecular interaction (dimerization), as well as the associated heterogeneities, of HER2 and its family member, the epidermal growth factor receptor (EGFR) in the plasma membrane of HER2 overexpressing breast cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
  18. 438
    “…To realize the diagnosis of HER2-positive gastric cancer via PET imaging, herein, a new kind of (18)F-labeled HER2 affibody probe was created; the bifunctional maleimide derivative 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA-MAL) was first coupled to a polypeptide, and the resulting compound was subsequently labeled with the (18)FAl complex. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
  19. 439
    por Zakeri, M, Li, J, Essien, EJ, Sansgiry, SS
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EPH20 Does a Mother's Previous Experience with COVID-19 Infection Change Her Intention to Vaccinate Her Children
  20. 440
    “…HER-1 and HER-2 are tumor-associated antigens overexpressed in several epithelial tumors, and successfully targeted by therapeutic approaches against cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology
Herramientas de búsqueda: RSS